FREELAND: CANADA WON'T ESCALATE OR BACK DOWN ON US TRADE FIGHT

MNI: PBOC To Aim To Drive Inflation Higher- Advisors

MNI: China To Issue More Bonds As Stimulus Targets Consumption

MNI: PBOC To Aim To Drive Inflation Higher- Advisors

MNI: China To Issue More Bonds As Stimulus Targets Consumption

MNI BRIEF: China Nov M1 Decline Narrows, M2 Slows

EZ/UK T-Bill Calendar: 8/13/28/50-Week BTF Auction on Monday

EZ/UK Bond Supply Calendar: 4.125% Jul-29 Gilt Due on Tuesday

MNI: CANADA OCT WHOLESALE SALES +3.3%; EX-AUTOS +0.5%

MNI EXCLUSIVE: EU-Mercosur Deal Close, But Likely Short-Lived - Officials

AUSTRALIA: 2025 Election Outcome Looking More Uncertain According To Newspoll

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

HEALTHCARE: Johnson & Johnson (JNJ Aaa/AAA neg): 3Q24

HEALTHCARE
BulletCredit Bullets

Solid results. Equity is up 1.5% overnight

  • Revenue $22.47bn +5.2% yoy. Ahead of consensus $22.2bn
  • Adj Net Earnings $5,876 down -13.3%
  • Innovative Medicine grew 4.9%
  • MedTech grew 5.8%
  • US sales outpaced International with 7.6% growth vs 2.3%
  • Growth in darzalex of 20.8% yoy offsets drop in stelara (-6.4%)
  • Guidance for Full Year increased to $88.6 (mid) from 88.2bn as positive impact of V-Wave feeds through
  • Talc settlement is still an unknown but the decision to hold the trial in Texas should help.
74 words

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.

Solid results. Equity is up 1.5% overnight

  • Revenue $22.47bn +5.2% yoy. Ahead of consensus $22.2bn
  • Adj Net Earnings $5,876 down -13.3%
  • Innovative Medicine grew 4.9%
  • MedTech grew 5.8%
  • US sales outpaced International with 7.6% growth vs 2.3%
  • Growth in darzalex of 20.8% yoy offsets drop in stelara (-6.4%)
  • Guidance for Full Year increased to $88.6 (mid) from 88.2bn as positive impact of V-Wave feeds through
  • Talc settlement is still an unknown but the decision to hold the trial in Texas should help.